BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer ModelsGlobeNewsWire • 04/21/26
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR MeetingGlobeNewsWire • 04/20/26
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 LicenseGlobeNewsWire • 03/31/26
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR ConferenceGlobeNewsWire • 03/18/26
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual MeetingGlobeNewsWire • 03/10/26
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 LicenseGlobeNewsWire • 02/18/26
BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune ActivationGlobeNewsWire • 01/28/26
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer PatientsGlobeNewsWire • 01/27/26
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ PatientGlobeNewsWire • 01/13/26
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature MedicineGlobeNewsWire • 12/18/25
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025GlobeNewsWire • 12/10/25
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data ReadoutGlobeNewsWire • 12/09/25
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025GlobeNewsWire • 11/25/25
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer TherapeuticsGlobeNewsWire • 11/20/25
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer ModelsGlobeNewsWire • 11/04/25
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast CancerGlobeNewsWire • 10/21/25